Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02944032 · ClinicalTrials.gov registry record · NA

Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1

A NA study of Neurofibromatosis Type 1, sponsored by Kristina Hardy.

Completed
Registry status
NA
Development phase
103
Enrollment target
1
Study location

NCT02944032: Completed NA study of Neurofibromatosis Type 1, sponsored by Kristina Hardy.

NCT02944032 is a NA study of Neurofibromatosis Type 1 that has completed, run by Kristina Hardy. The registered enrollment target is 103 participants, below the 155-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02944032, a NA study of Neurofibromatosis Type 1, has completed, sponsored by Kristina Hardy.

COMPLETED
Registry status
NA
Development phase
103 participants
Enrollment target
1
Study location

Study Summary

The main objective of the study is to assess the efficacy of a home-based, computerized cognitive training (CT) program, called CogmedRM, targeted to improve working memory in children with NF1 and working memory difficulties. This is a Phase II randomized parallel group controlled clinical trial comparing two interventions on cognitive outcomes. Participants will be stratified by stimulant medication use and randomized equally between the two interventions within stratum. Participants will be in the study for to 11 weeks.

Primary Outcome

Computerized task of working memory

Conditions Studied

Interventions

  • OTHER CogmedRM
  • OTHER Mobymax

Study Locations (1)

District of Columbia

  • Children's National Health System - Washington D.C.

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2016-05
Est. Completion 2021-09-27
Phase NA
Kristina Hardy

1 total trials

What the finished NCT02944032 record still lists

NCT02944032 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 155-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (34% lower).

The record links to 1 condition, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 2 interventions - of which CogmedRM is the first listed.

NCT02944032 reports a single indexed study location in District of Columbia.

Frequently Asked Questions

What is clinical trial NCT02944032 about?

NCT02944032 is a clinical study titled "Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1". The main objective of the study is to assess the efficacy of a home-based, computerized cognitive training (CT) program, called CogmedRM, targeted to improve working memory in children with NF1 and working memory difficulties. This is a Phase II randomized parallel group controlled clinical trial co...

What is the current status of trial NCT02944032?

This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2016-05. Estimated completion is 2021-09-27.

What conditions does trial NCT02944032 study?

This clinical trial studies the following conditions: Neurofibromatosis Type 1.

What interventions are being tested in trial NCT02944032?

The interventions under investigation include: CogmedRM (OTHER), Mobymax (OTHER).

Who is sponsoring clinical trial NCT02944032?

This trial is sponsored by Kristina Hardy, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02944032 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurofibromatosis Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02944032's enrollment target sits among peer trials

103 7th of 17 higher than 11 of 17 other Neurofibromatosis Type 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neurofibromatosis Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02944032, the US trial registry maintained by the National Library of Medicine. NCT02944032 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.